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Abstract
Irisin and FGF21 are novel hormones implicated in the ‘‘browning’’ of white fat, thermogenesis, and energy homeostasis.
However, there are no data regarding these hormones in amenorrheic athletes (AA) (a chronic energy deficit state)
compared with eumenorrheic athletes (EA) and non-athletes. We hypothesized that irisin and FGF21 would be low in AA, an
adaptive response to low energy stores. Furthermore, because (i) brown fat has positive effects on bone, and (ii) irisin and
FGF21 may directly impact bone, we hypothesized that bone density, structure and strength would be positively associated
with these hormones in athletes and non-athletes. To test our hypotheses, we studied 85 females, 14–21 years [38 AA, 24 EA
and 23 non-athletes (NA)]. Fasting serum irisin and FGF21 were measured. Body composition and bone density were
assessed using dual energy X-ray absorptiometry, bone microarchitecture using high resolution peripheral quantitative CT,
strength estimates using finite element analysis, resting energy expenditure (REE) using indirect calorimetry and time spent
exercising/week by history. Subjects did not differ for pubertal stage. Fat mass was lowest in AA. AA had lower irisin and
FGF21 than EA and NA, even after controlling for fat and lean mass. Across subjects, irisin was positively associated with REE
and bone density Z-scores, volumetric bone mineral density (total and trabecular), stiffness and failure load. FGF21 was
negatively associated with hours/week of exercise and cortical porosity, and positively with fat mass and cortical volumetric
bone density. Associations of irisin (but not FGF21) with bone parameters persisted after controlling for potential
confounders. In conclusion, irisin and FGF21 are low in AA, and irisin (but not FGF21) is independently associated with bone
density and strength in athletes.
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Introduction
Irisin and FGF21 are novel hormones implicated in the
modulation of energy homeostasis [1], and more recently with
bone metabolism. A recently discovered myokine and adipokine,
irisin has been proposed to be an important mediator of the
beneficial metabolic effects of exercise [2]. It is released
systemically from skeletal muscle and induces the ‘‘browning’’ of
subcutaneous white adipocytes, uncoupling protein 1 (UCP1)-
mediated thermogenesis, and increased energy expenditure [2].
Irisin secretion also increases in men who exercise [2,3]. However,
the impact of chronic exercise on irisin in over-exercising females
has not been examined, and the impact of associated hypotha-
lamic amenorrhea is unknown.
FGF21 is secreted into the circulation from the adipocytes and
liver, and is expressed in fat, skeletal muscle and the pancreas.
FGF21 regulates carbohydrate and lipid metabolism, resulting in
improved glucose homeostasis and lipid parameters, and reduces
body weight in animal models. Like irisin, FGF21 promotes
conversion of white to beige adipose tissue, activation of UCP1-
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E-mail: These authors are joint first authors on this work. "driven thermogenesis and energy expenditure, although this may
represent an autocrine/paracrine rather than endocrine effect
[4,5]. A positive relationship between FGF21 and physical activity
has been described [6], and initiation of an exercise regimen in
sedentary young women leads to increased FGF21 [7].
In addition, both irisin and FGF21 have been implicated in
bone metabolism. Brown adipose tissue is an independent
predictor of bone density in women [8], and the volume and
activity of brown adipose tissue is positively associated with total
and cortical bone cross-sectional area in young children and
adolescents [9]. In rodent models, irisin increases trabecular and
cortical thickness as well as trabecular density through increased
osteoblast activation and inhibition of RANKL mediated osteo-
clastogensis [10]. Effects of FGF21 on bone are still being defined,
with one study demonstrating deleterious effects on bone through
inhibition of osteoblastogenesis in favor of adipogenesis [11]
whereas a study in adult females reported a positive association
between FGF21 and bone density [12] supported by in vitro data
[13]. Thus irisin and FGF21 may impact bone both through
induction of brown adipogenesis, as well as through direct effects.
Data are lacking regarding associations of irisin and FGF21 with
bone parameters in athletes and non-athletes, and the impact of a
hypogonadal state (in athletes with functional hypothalamic
amenorrhea) on these associations.
Although exercise may increase irisin and FGF21 levels in
healthy individuals, we hypothesized that levels of irisin and
FGF21 would be low in amenorrheic athletes, signaling an
adaptive response to an overall state of energy deficit. In addition,
we hypothesized that irisin and FGF21 levels would be positively
associated with measures of bone density, structure and strength in
athletes and non-athletes.
Subjects and Methods
Subjects
We studied 85 adolescent women [38 amenorrheic athletes
(AA), 24 eumenorrheic athletes (EA) and 23 non-athletes] between
14–21 years of age enrolled in an ongoing study, all of whom were
.85% ideal body weight based on the 50
th percentile for BMI for
age. Clinical characteristics of a subgroup of these women have
been previously reported [14,15,16,17]. However, levels of irisin
and FGF21, and the relationship between irisin and FGF21 levels
and measures of bone metabolism have not been previously
described. All study participants were recruited from the
community through advertisements and referrals from healthcare
providers. We defined ‘amenorrhea’ as absence of menses for 3
months in a 6-month period of oligo-amenorrhea (cycle length
greater than 6 weeks) or absence of menses at $15 years (upper
limit of normal for menarche), after other causes of amenorrhea
were ruled out. Duration since last menses in AA (median and
interquartile range) was 165 (24–360) days. We defined eumenor-
rheic athletes as those who had had $9 menses in the previous
year. Three athletes (all less than 17 years old) had not attained
menarche, and other causes of menarchal delay (other than
excessive exercise) were ruled out in these athletes.
Inclusion criteria for athletes included $4 hours of aerobic
weight-bearing activity or $20 miles of running weekly for the
preceding 6 months. Inclusion criteria for non-athletes included ,
2 hours per week of weight-bearing activities. Per study design, no
subject met criteria for anorexia nervosa at study enrollment,
although 34% of AA and 4% of EA had a past or current history
of some form of disordered eating behavior. The racial distribution
included 81.0% White or Asian, 13.1% Mixed and 6.0% Black,
while the ethnic distribution included 95.2% non-Hispanic and
4.8% Hispanic. Race and ethnic distribution did not differ
significantly across groups.
Subjects were recruited from local area high schools and
colleges and referrals from pediatricians, adolescent medicine
physicians, endocrinologists, nutritionists and sports medicine
physicians. All subjects who met inclusion criteria were included in
the study in a consecutive fashion.
Ethics Statement
The study was approved by the Institutional Review Board
(IRB) of the Partners HealthCare system (Protocol 2009-P-
000353). Per IRB guidelines and using IRB approved consent
and assent forms, (i) informed written consent was obtained from
subjects $18 years old and parents of subjects ,18 years, and (ii)
informed written assent was obtained from subjects ,18 years.
Study Design
Subjects were seen in the Clinical Research Center of
Massachusetts General Hospital. The screening visit included a
history and physical examination, and laboratory evaluations to
rule out conditions other than excessive exercise accompanied by
inadequate caloric intake that may cause hypothalamic amenor-
rhea. We thus ruled out hyperprolactinemia, primary ovarian
failure, polycystic ovarian syndrome (PCOS) and thyroid dysfunc-
tion.
Qualifying subjects underwent a history and physical examina-
tion, assessment of hours per week of physical activity (averaged
over a year) and measurement of fasting resting energy expendi-
ture using the VMAX Encore 29 metabolic cart (Viasys
Healthcare, Carefusion; San Diego, CA) [18,19]. Subjects did
not alter their usual food intake in the days preceding the study
visit. Similarly, exercise activity on the days preceding the study
visit was not curtailed to allow for usual levels of physical activity.
However, fasting morning blood for irisin and FGF-21 levels was
drawn before any exercise activity. EA and non-athletes were
assessed in the early to mid follicular phase of their cycles (based
on menstrual history). All subjects had assessment of (i) body
composition and areal bone density (spine, hip and whole body)
using dual energy x-ray absorptiometry (DXA), and a subset were
assessed for (ii) bone microarchitecture and estimates of strength at
the distal radius (site of non-weight bearing bone) using high
resolution peripheral quantitative computed tomography
(HRpQCT) and finite element analysis (FEA) using published
methods [14,15,16]. FEA-derived estimates of failure load using
these methods are strongly correlated (r
2=0.75) with experimen-
tally measured failure loads that produce Colles’ fractures in
human cadaveric radii. HR-pQCT data were acquired on a single
instrument by one operator, who performed standard evaluations
(periosteal contouring). All finite element analyses (endosteal
contouring) were also performed by one blinded investigator [15].
Biochemical Analysis
We used an ELISA to measure irisin (Adipogen; Liestal,
Switzerland; intra-assay coefficient of variation (CV) 6.9%, inter-
assay CV 9.07%, detection limit 0.001 mcg/mL) and FGF21
(R&D Systems; Minneapolis, MN; intra-assay CV 3.4%, inter-
assay CV 7.5%, detection limit 4.67 pg/mL). For the irisin assay,
the laboratory evaluated thee different assay kits on the number of
standards (assay range), sample type (serum or plasma), sample
volume, sample dilution, assay range, sensitivity, assay time and
cost. The Adipogen assay was chosen because it had the greatest
detection range (0.001–5 ug/mL), required the least volume of
sample, and was the most sensitive (0.001 mcg/mL). This was
important given the limited studies of irisin in the pediatric age
Irisin and Bone in Athletes and Non-Athletes
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pediatric population. Of note, this assay reports irisin levels that
are an order of magnitude higher than the Phoenix Pharmaceu-
ticals assay [20]. All samples were processed immediately and
stored at 280 degrees Celsius until they were analyzed to
minimize peptide degradation, and contrary to one study that
demonstrated inverse associations of irisin levels with duration of
sample storage [21], we found no such inverse association of irisin
or FGF-21 levels with duration of storage. In fact, another study
found no impact of repeated freeze thaw cycles on irisin levels
[22], suggesting relative stability of this peptide hormone.
A chemiluminescent immunoassay was used to measure 25-
hydroxyvitamin D (DiaSorin, Stillwater, MN; intraassay CV 2.9–
5.5%, interassay CV 8%; sensitivity 4 ng/ml). A subset of at least
55 subjects were assessed for P1NP, CTX, testosterone, SHBG
and estradiol levels. We used an RIA to measure P1NP (Orion
Diagnostics, Espoo, Finland; intra-assay CV 3.5–5.3%, inter-assay
CV 3.6–5.4%), lower limit of detection 0.7 ng/ml), and an IRMA
to measure CTX (Immunodiagnostics Systems, Fountain Hills,
AZ; intra-assay CV 5.2–6.8%, inter-assay CV 5.6–7.4%, lower
limit of detection 0.02 ng/ml). Testosterone was measured by RIA
(Diagnostic Products Corp, Los Angeles, CA; intra-assay CV 5?1–
9?8%, inter-assay CV 8.2%, limit of detection 12 ng/dl), SHBG
by IRMA (Diagnostic Products Corp, intra-assay CV 2?8–5?3%,
inter-assay CV 8.2%, limit of detection 3 nmol/l), and estradiol by
ultrasensitive ELISA (ALPCO Diagnostics, Salem, NH; intra-
assay CV of 6.36% and inter-assay CV of 7.6%, minimum level of
detection 1.4 pg/mL). Free androgen index (FAI) was calculated
using the following formula: [total testosterone (nmol/l)6100]/
SHBG (nmol/l) [23]. All blood samples were spun immediately
after collection, and the serum separated and stored in 280 degree
Celsius freezers until analysis in duplicate.
Statistical Analysis
JMP Statistical Discoveries (version 10.0; SAS Institute, Inc.,
Cary, NC) was used for statistical analyses. Our sample size had .
80% power for detecting a significant difference between AA and
control groups for irisin and FGF21 respectively at an alpha level
of 0.05 based on published data [24,25]. Clinical characteristics,
hormone levels and bone parameters were compared across the
three groups (AA, EA and non-athletes) using analysis of variance
(ANOVA). Irisin and FGF21 levels were logarithmically trans-
formed prior to analyses to approximate a normal distribution.
When the overall ANOVA had a significant p-value, the Tukey
Kramer test was used to compare differences between groups
while controlling for multiple comparisons. For non-parametric
comparisons of three groups, we used the Kruskal-Wallis test
followed by the Steel-Dwass method for between group compar-
isons.
We used Pearson or Spearman correlations (depending on data
distribution) to determine associations of hormones with bone
measures, body composition and REE. Because irisin is a myokine,
associations of irisin with these measures may differ in chronically
exercising athletes compared with non-athletes. In addition,
amenorrhea may modify associations of irisin with various
parameters within athletes. For these reasons, we performed
exploratory analyses of associations of irisin and FGF21 not only
for the group as a whole, but also within AA, EA, all athletes (AA+
EA), and non-athletes. Multivariate least-square analyses were
constructed to control for confounders and to test interactions
between subject group and hormone levels. Significance was
defined as a two-tailed p-value ,0.05. Data are reported as mean
6 SD.
Results
Subject Characteristics
Subject characteristics are presented in Table 1. AA were
slightly older than the other groups, although bone age and
Tanner stage did not differ among groups. Mean duration since
the last menstrual cycle in AA was 9.762.4 months, and
menarchal age was older in AA than in EA and non-athletes.
BMI was lower in AA than EA. Total fat mass was lower in AA
than EA and non-athletes, and lean mass was higher in EA than in
non-athletes. Percent body fat was lower in both groups of athletes
versus non-athletes and in AA compared to EA. By design, hours
of weekly exercise were higher in AA and EA than non-athletes
(with no difference between AA and EA). Resting energy
expenditure (REE) was higher in EA than AA and non-athletes.
After controlling for lean mass, resting energy expenditure
remained higher in EA than AA. REE/lean mass was lowest in
AA.
Bone parameters are shown in Table 2 and have been
previously reported for a subset of 50 subjects [14,15,16]. Spine
BMD Z-scores were lower in AA than EA, whereas hip and whole
body BMD Z-scores were highest in EA. Trabecular and cortical
volumetric BMD (vBMD), cortical thickness, stiffness and failure
load were lower and cortical porosity higher in AA than in non-
athletes, and percent cortical area was lower in both groups of
athletes compared with non-athletes. Differences among groups
remained significant for most parameters after controlling for age,
and for age and race (Table 2). Levels of P1NP (a bone formation
marker) and CTX (a bone resorption marker) were available for a
subset of 55 subjects. P1NP levels did not differ across groups
(88.1637.9, 98.4655.2 and 83.8638.3 ng/ml in AA, EA and
non-athletes respectively, p=0.60). CTX levels trended higher in
the athletes (1.0660.33, 1.1660.39 and 0.9160.30 ng/ml in AA,
EA and non-athletes respectively, p=0.09). Estradiol levels and
the free androgen index (while lowest in AA) did not differ
significantly across groups.
Hormone Levels
Table 1 and Figure 1 demonstrate levels of irisin and FGF21
across the groups. Irisin and FGF21 levels were significantly lower
in AA than EA and non-athletes, and these differences persisted
after controlling for age (p=0.0001 for both for the overall
ANOVA), or for body fat and lean mass (p,0. 05), while there
were no differences in hormone levels between EA and non-
athletes. Log irisin and log FGF21 correlated positively with each
other within athletes (r=0.26, p=0.04), but the association was
inverse in non-athletes (r=20.50, 0.01). Within individual athlete
groups, associations were weaker, and mostly driven by AAs (AA:
Spearman Rho=0.28, p=0.09; EA: Spearman Rho=0.13,
p=0.54). Our results remained similar when we excluded the
three athletes who had not attained menarche from the analysis.
Relationship between Hormone Levels, Measures of
Energy Expenditure and Measures of Body Composition
Associations of irisin with measures of energy expenditure and
body composition are shown in Table 3. Irisin was positively
associated with resting energy expenditure in the group as a whole,
within athletes and also non-athletes. However, associations were
not significant for AA and EA analyzed separately. We found no
associations of irisin with hours/week of exercise or fat mass in any
of the groups. Log irisin was positively associated with lean mass in
all athletes and within AA, but not in EA, non-athletes or the
group as a whole.
Irisin and Bone in Athletes and Non-Athletes
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body composition are shown in Table 4. Log FGF21 was
associated inversely with resting energy expenditure in EA and
non-athletes, but not in the other groups. Across all groups, there
were negative associations between log FGF21 and with hours/
week of exercise, and positive associations with body fat content.
Within individual groups, we found no associations of log FGF21
with hours/week of exercise, or percent body fat mass. There were
no associations of log FGF21 with lean mass. Irisin and FGF21
levels were overall not associated with age (p=0.52 and 0.85
respectively), or bone age (p=0.89 and 0.61).
Relationship between Hormone Levels and Sex Steroids
Log irisin levels were associated positively with the free
androgen index in AA (r=0.63, p=0.002), and with estradiol in
non-athletes (rho=0.46, p=0.05). Log FGF21 was associated
positively with the free androgen index in AA (r=0.55, p=0.009)
and inversely with estradiol levels in non-athletes (r=20.63,
p=0.005). Associations of irisin and FGF21 with the free
androgen index (but not estradiol) remained significant after
controlling for fat mass or lean mass.
Relationship between Hormone Levels and Bone
Parameters
Across all groups, irisin levels were positively associated with
spine, femoral neck and whole body BMD Z scores (Table 3).
Irisin levels were also associated with total and trabecular vBMD,
and with bone strength estimates, including stiffness and failure
load. All associations appeared to be driven mostly by the athletes
taken together (AA and EA). Associations within AA and EA
groups were weaker. Table 3 also shows associations that
remained significant after controlling for (i) lean mass, (ii) lean
mass and activity levels, and (iii) lean mass, fat mass and activity
levels. In contrast, the only associations observed between FGF21
and bone parameters were a positive association with cortical
volumetric BMD, and an inverse association with cortical porosity
for all groups taken together, and inverse associations with total
and trabecular vBMD in non-athletes.
We tested for interactions between subject groups and irisin and
FGF21 in determining associations of irisin with bone parameters
across groups, and our analysis did not show strong evidence that
the patterns of irisin effects on bone outcomes were different across
subgroups.
Across all groups, the association of irisin with whole body
BMD Z-scores, total and trabecular vBMD, percent cortical area,
cortical thickness, stiffness and failure load were significant after
controlling for FGF21 and lean mass (p=0.01, 0.04, 0.02, 0.05,
0.04, 0.02, 0.02 and 0.04 respectively). In addition, spine and
whole body BMD Z-scores, stiffness and failure load remained
significantly associated with irisin after controlling for FGF21, lean
mass and hours/week of exercise (p=0.03, 0.01, 0.05 and 0.04
respectively), and for FGF21, lean and fat mass and hours/week of
exercise (p=0.04, 0.01, 0.06 and 0.04 respectively). Within
athletes, the association between irisin and spine and whole body
BMD Z-scores remained significant after controlling for FGF21,
lean and fat mass, and hours/week of exercise. A trend persisted
for the negative association between FGF21 and cortical porosity
after controlling for irisin and lean mass (p=0.08), but not after
controlling for hours/week of activity and/or fat mass. Our results
were similar when we excluded the three premenarchal athletes
from our analysis.
Discussion
This is the first study to demonstrate low levels of irisin and
FGF-21 in adolescent amenorrheic athletes, which we speculate
represents an adaptive response to conserve energy in these young
women. Irisin levels were associated with resting energy expen-
diture and FGF-21 with body fat content. Importantly, irisin levels
were associated with measures of areal and volumetric bone
density and strength estimates in athletes, and associations with
bone density and strength measures persisted after controlling for
potential confounders. In contrast, FGF21 levels were associated
with only a few bone parameters.
Irisin and FGF-21 promote the ‘‘browning’’ of white adipose
tissue, resulting in ‘‘beige fat’’, a metabolically favorable fat
capable of burning energy through thermogenesis. This special-
ized tissue has features of brown fat, including multilocular fat
cells, an abundance of mitochondria, and UCP-1, an enzyme that
uncouples oxidative phosphorylation from ATP production,
leading to energy release as heat [2,4].
Irisin levels have not been previously reported in adolescent
female athletes. One study suggested that in moderately trained
young healthy male athletes, plasma irisin levels are increased
30 minutes after sprinting, but this effect is not seen after eight
weeks of training [3]. In another study, initiation of an endurance
exercise routine in sedentary men led to a two-fold rise in plasma
irisin levels at ten weeks [2], while a third study in adults reported
Figure 1. Irisin and FGF21 levels in athletes and non-athletes. (A) Irisin and (B) FGF21 levels were lower in amenorrheic athletes (AA)
compared to eumenorrheic athletes (EA) and non-athletes (NA) (ANOVA for three-group comparison for log converted values, followed by the Tukey
Kramer test to compare any two groups). *, p,0.05 vs. EA and NA.
doi:10.1371/journal.pone.0100218.g001
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irisin after a 12-week period of endurance and strength training
[26]. We found that irisin levels were lower in AA compared to EA
and non- athletes, and these differences persisted after controlling
for fat and lean mass. Our data likely reflect the effects of chronic
exercise on irisin levels, in contrast to some previous studies that
examined effects of short-durations of exercise on irisin secretion.
Our data are consistent with a study of adult men that reported
inverse associations of irisin with regular exercise related physical
activities [27]. Furthermore, irisin levels were positively associated
with resting energy expenditure. Irisin levels did not differ between
EA and non-athletes in our study, suggesting that chronic exercise
does not affect irisin levels in the setting of eumenorrhea and
preserved energy stores. Decreased irisin levels in AA likely
represent an adaptive response in chronic exercisers to reduce
REE and conserve energy by reducing brown adipogenesis. This is
corroborated by reports of lower irisin levels [25] and lower
occurrence of brown fat in conditions of extreme malnutrition,
such as anorexia nervosa [28], reductions in circulating irisin
following marked weight loss in patients after bariatric surgery
[22], and increased levels in obesity [25].
We did not assess brown fat in our subjects, and this is an area
of future study. Of note, although our AA subjects had lower BMI
than EA, their BMI was not as low as in girls with anorexia
nervosa. Thus, these AA subjects are in a state of subtle energy
deficit as indicated by their reduced fat mass and lower resting
energy expenditure after correcting for lean mass, but not in the
state of extreme energy deficit observed in anorexia nervosa.
Another small study in patients with anorexia nervosa assessed
irisin levels in those reporting moderate vs. high levels of physical
activity, and found no differences in BMI, REE or irisin levels
across groups, although the higher activity group had higher total
energy expenditure [29]. These data suggest that irisin drives
changes in REE (or vice versa), but not in total energy
expenditure, consistent with irisin being an inducer of brown
adipogenesis (and driver of REE), and the positive associations of
irisin with REE in our subjects.
In addition, consistent with irisin being a myokine and with
other studies that have reported positive associations of irisin with
muscle mass [22,25,30], we observed positive associations of irisin
with lean mass in athletes. Other studies have reported positive
associations of irisin with nutritional markers such as BMI, fat
mass, IGF-1 and insulin, and with markers of the metabolic
syndrome such as higher blood pressure, insulin resistance and
lipid levels, [22,25,27]. Higher irisin levels in obesity, and in
patients with the metabolic syndrome may represent a physiolog-
ical response to improve glucose tolerance and lipid parameters in
these individuals [25,26,27]. One study reported lower irisin levels
in patients with type 2 diabetes than controls of similar BMI,
which may represent a failure of this physiological response
leading to diabetes [31]. However, a study in obese children
reported an increase (rather than a decrease in irisin levels after a
year of exercise and lifestyle intervention [32]. These seemingly
conflicting data speak to the complexity of irisin interactions with
metabolic endpoints, and the need for further studies to clarify the
role of irisin as a regulator of metabolism. We found no
associations of irisin with fat mass in our study, maybe because
we assessed only lean individuals in our cohort.
Of interest, irisin levels were higher in our study than reported
in many previous studies, likely consequent to differences in the
specific assay used for analysis [20] and the younger age of our
subjects. Some studies have reported inverse associations of irisin
with age [22,33], and several fold higher irisin levels in young
adult men compared with middle aged women [22].
Moreover, irisin has a potential role in modulating bone
metabolism through direct [10,34] and indirect (brown fat
mediated) effects. A recent study demonstrates that irisin may
affect osteoblastogenesis via the Wnt/beta-catenin pathway
downstream of the BMP receptor signal, and also inhibits
osteoclast differentiation [10]. Furthermore, in vivo studies indicate
that irisin increases bone trabecular volume and cortical thickness
in mice [10]. Our data are consistent in that irisin levels predicted
trabecular volumetric BMD measures in addition to other
measures of bone density and strength estimates in athletes.
Effects of irisin on bone may also be mediated via induction of
brown adipogenesis given reports of associations of brown fat with
bone strength estimates in women [8], and with cortical thickness
in children and adolescents [9]. In adult women, lower irisin levels
have been associated with a higher risk of osteoporotic fractures
[33].
Similar to irisin, FGF21 levels increase with acute or short
durations of exercise [35,36], decrease with regular exercise and
caloric restriction in animals and humans [37,38], decrease in
extreme states of malnutrition (as in anorexia nervosa) related to
BMI [24], and increase in obesity and the metabolic syndrome
related to fat mass [39,40,41]. Given known effects of FGF21 in
inducing brown adipogenesis [4,5] and increasing REE, these
changes likely represent an adaptive response to decrease brown
adipogenesis and conserve energy in anorexia nervosa, and to
increase brown adipogenesis and expend energy in obesity.
Conversely, these changes may also signal an FGF21 resistant
state. Consistent with the study in women with anorexia nervosa
[24], we found that FGF21 levels were low in AA compared to EA
and non athletes and inversely associated with hours per week of
exercise, likely again an adaptive response to conserve energy. In
contrast, a study of sedentary healthy young women reported an
increase in FGF-21 levels after two-weeks of exercise [24],
suggesting that short-term energy expenditure in sedentary women
may result in increases in FGF-21 whereas longer-term chronic
energy expenditure leads to decreased FGF-21 to preserve energy.
FGF21 also impacts bone metabolism, although available reports
are contradictory with some studies indicating beneficial [12,13],
and others indicating deleterious [11] effects of FGF21 on bone. In
our study, FGF21 was associated positively with cortical volumet-
ric BMD and inversely with cortical porosity for the group taken
together, consistent with a beneficial effect of FGF21 on bone.
However, associations were lost after controlling for irisin, body
composition and exercise activity. Further studies are needed to
clarify effects of FGF-21 on bone.
Few studies have examined associations of irisin and FGF21
with the sex steroids. We observed positive associations of both
hormones with the free androgen index in AA. However,
associations of these hormones with estradiol were conflicting,
with positive associations noted with irisin and inverse associations
with FGF21 in non-athletes. Of interest, positive associations of
FGF21 with testosterone levels have been reported in women with
polycystic ovarian syndrome (PCOS) [42], and positive associa-
tions of irisin and FGF21 with testosterone levels may reflect
associations of these hormones with components of the metabolic
syndrome. Although one study reported higher FGF21 levels in
women with PCOS than in those without this condition, another
study found no differences in FGF21 across groups [43].
Conclusions
We report low levels of irisin and FGF-21 in young amenorrheic
athletes compared with eumenorrheic athletes and non-athletes,
even after taking into account fat and lean mass. In addition, we
Irisin and Bone in Athletes and Non-Athletes
PLOS ONE | www.plosone.org 9 June 2014 | Volume 9 | Issue 6 | e100218demonstrate that irisin levels are a determinant of measures of
areal and volumetric bone mineral density and bone strength
estimates in athletes, but not non-athletes. While this is the first
study to report levels of irisin and FGF21 in adolescent female
athletes and non-athletes, it is a cross-sectional study and therefore
causality cannot be inferred from our data. Further research
regarding the role of these hormones in regulating bone
metabolism will be important.
Author Contributions
Conceived and designed the experiments: MM. Performed the experi-
ments: VS KEA HC KE DAM NPD MLB MM. Analyzed the data: VS
EAL HL MM. Wrote the paper: VS EAL PKF MM.
References
1. Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, et al. (2014) Irisin and
FGF21 are cold-induced endocrine activators of brown fat function in humans.
Cell Metab 19: 302–309.
2. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, et al. A PGC1-alpha-
dependent myokine that drives brown-fat-like development of white fat and
thermogenesis. Nature 481: 463–468.
3. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, et al. FNDC5
and irisin in humans: I. Predictors of circulating concentrations in serum and
plasma and II. mRNA expression and circulating concentrations in response to
weight loss and exercise. Metabolism 61: 1725–1738.
4. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, et al. FGF21 regulates
PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis.
Genes Dev 26: 271–281.
5. Lee P, Brychta RJ, Linderman J, Smith S, Chen KY, et al. Mild cold exposure
modulates fibroblast growth factor 21 (FGF21) diurnal rhythm in humans:
relationship between FGF21 levels, lipolysis, and cold-induced thermogenesis.
J Clin Endocrinol Metab 98: E98–102.
6. Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ, Meza-Arana CE, Cruz-
Bautista I, et al. Daily physical activity, fasting glucose, uric acid, and body mass
index are independent factors associated with serum fibroblast growth factor 21
levels. Eur J Endocrinol 163: 469–477.
7. Cuevas-Ramos D, Almeda-Valdes P, Meza-Arana CE, Brito-Cordova G,
Gomez-Perez FJ, et al. Exercise increases serum fibroblast growth factor 21
(FGF21) levels. PLoS One 7: e38022.
8. Lee P, Brychta RJ, Collins MT, Linderman J, Smith S, et al. (2012) Cold-
activated brown adipose tissue is an independent predictor of higher bone
mineral density in women. Osteoporos Int 24: 1513–1518.
9. Ponrartana S, Aggabao PC, Hu HH, Aldrovandi GM, Wren TA, et al. (2012)
Brown adipose tissue and its relationship to bone structure in pediatric patients.
J Clin Endocrinol Metab 97: 2693–2698.
10. Zhang J, Cheng J, Tu Q, Chen J (2013) Effects of Irisin on Bone Metabolism
and its Signal Transduction ASBMR 2013 Book of Abstracts.
11. Wei W, Dutchak PA, Wang X, Ding X, Bookout AL, et al. (2012) Fibroblast
growth factor 21 promotes bone loss by potentiating the effects of peroxisome
proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 109: 3143–
3148.
12. Lee P, Linderman J, Smith S, Brychta RJ, Perron R, et al. (2013) Fibroblast
growth factor 21 (FGF21) and bone: is there a relationship in humans?
Osteoporos Int.
13. Ishida K, Haudenschild DR (2013) Interactions between FGF21 and BMP-2 in
osteogenesis. Biochem Biophys Res Commun 432: 677–682.
14. Ackerman KE, Nazem T, Chapko D, Russell M, Mendes N, et al. (2011) Bone
microarchitecture is impaired in adolescent amenorrheic athletes compared with
eumenorrheic athletes and nonathletic controls. J Clin Endocrinol Metab 96:
3123–3133.
15. Ackerman K, Putman M, Guereca G, Taylor A, Pierce L, et al. (2012) Cortical
Microstructure and Estimated Bone Strength in Young Amenorrheic Athletes,
Eumenorrheic Athletes and Non-Athletes. Bone In Press.
16. Lawson EA, Ackerman KE, Estella NM, Guereca G, Pierce L, et al. (2013)
Nocturnal oxytocin secretion is lower in amenorrheic athletes than nonathletes
and associated with bone microarchitecture and finite element analysis
parameters. Eur J Endocrinol 168: 457–464.
17. Fazeli PK, Ackerman KE, Pierce L, Guereca G, Bouxsein M, et al. (2013)
Sclerostin and Pref-1 have differential effects on bone mineral density and
strength parameters in adolescent athletes compared with non-athletes.
Osteoporos Int 24: 2433–2440.
18. Harris JA, Benedict FG (1918) A Biometric Study of Human Basal Metabolism.
Proc Natl Acad Sci U S A 4: 370–373.
19. Weir JB (1949) New methods for calculating metabolic rate with special
reference to protein metabolism. J Physiol 109: 1–9.
20. Peter PR, Park KH, Huh JY, Wedick NM, Mantzoros CS (2014) Circulating
irisin levels are not affected by coffee intake: a randomized controlled trial. PLoS
One 9: e94463.
21. Hecksteden A, Wegmann M, Steffen A, Kraushaar J, Morsch A, et al. (2013)
Irisin and exercise training in humans - results from a randomized controlled
training trial. BMC Med 11: 235.
22. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, et al. (2012)
FNDC5 and irisin in humans: I. Predictors of circulating concentrations in
serum and plasma and II. mRNA expression and circulating concentrations in
response to weight loss and exercise. Metabolism 61: 1725–1738.
23. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, et al. (2004) Measurement of
free testosterone in normal women and women with androgen deficiency:
comparison of methods. J Clin Endocrinol Metab 89: 525–533.
24. Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, et al. (2008)
Plasma concentrations of fibroblast growth factors 19 and 21 in patients with
anorexia nervosa. J Clin Endocrinol Metab 93: 3627–3632.
25. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, et al. (2013)
Circulating levels of irisin in patients with anorexia nervosa and different stages
of obesity–correlation with body mass index. Peptides 39: 125–130.
26. Norheim F, Langleite TM, Hjorth M, Holen T, Kielland A, et al. (2014) The
effects of acute and chronic exercise on PGC-1alpha, irisin and browning of
subcutaneous adipose tissue in humans. FEBS J 281: 739–749.
27. Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, et al. (2013)
Circulating irisin in relation to insulin resistance and the metabolic syndrome.
J Clin Endocrinol Metab 98: 4899–4907.
28. Bredella MA, Fazeli PK, Freedman LM, Calder G, Lee H, et al. (2012) Young
women with cold-activated brown adipose tissue have higher bone mineral
density and lower Pref-1 than women without brown adipose tissue: a study in
women with anorexia nervosa, women recovered from anorexia nervosa, and
normal-weight women. J Clin Endocrinol Metab 97: E584–590.
29. Hofmann T, Elbelt U, Ahnis A, Kobelt P, Rose M, et al. (2014) Irisin Levels are
Not Affected by Physical Activity in Patients with Anorexia Nervosa. Front
Endocrinol (Lausanne) 4: 202.
30. Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, et al. (2014) Effects of
obesity, diabetes and exercise on Fndc5 gene expression and irisin release in
human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol
592: 1091–1107.
31. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, et al. (2013)
Irisin is expressed and produced by human muscle and adipose tissue in
association with obesity and insulin resistance. J Clin Endocrinol Metab 98:
E769–778.
32. Bluher S, Panagiotou G, Petroff D, Markert J, Wagner A, et al. (2014) Effects of
a 1-year exercise and lifestyle intervention on irisin, adipokines, and
inflammatory markers in obese children. Obesity (Silver Spring).
33. Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, et al. (2014)
Circulating irisin is associated with osteoporotic fractures in postmenopausal
women with low bone mass but is not affected by either teriparatide or
denosumab treatment for 3 months. Osteoporos Int 25: 1633–1642.
34. Colaianni G, Cuscito C, Mongelli T, Oranger A, Mori G, et al. (2014) Irisin
enhances osteoblast differentiation in vitro. Int J Endocrinol 2014: 902186.
35. Kim KH, Kim SH, Min YK, Yang HM, Lee JB, et al. (2013) Acute exercise
induces FGF21 expression in mice and in healthy humans. PLoS One 8: e63517.
36. Cuevas-Ramos D, Almeda-Valdes P, Meza-Arana CE, Brito-Cordova G,
Gomez-Perez FJ, et al. (2012) Exercise increases serum fibroblast growth factor
21 (FGF21) levels. PLoS One 7: e38022.
37. Fletcher JA, Meers GM, Laughlin MH, Ibdah JA, Thyfault JP, et al. (2012)
Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily
exercise and caloric restriction. Appl Physiol Nutr Metab 37: 1054–1062.
38. Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, et al. (2011) Effects of a three-
month combined exercise programme on fibroblast growth factor 21 and fetuin-
A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf) 75: 464–
469.
39. Reinehr T, Woelfle J, Wunsch R, Roth CL Fibroblast growth factor 21 (FGF-21)
and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in
children: a longitudinal analysis. J Clin Endocrinol Metab 97: 2143–2150.
40. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, et al. (2008) Serum
FGF21 levels are increased in obesity and are independently associated with the
metabolic syndrome in humans. Diabetes 57: 1246–1253.
41. Shen Y, Ma X, Zhou J, Pan X, Hao Y, et al. (2013) Additive relationship
between serum fibroblast growth factor 21 level and coronary artery disease.
Cardiovasc Diabetol 12: 124.
42. Gorar S, Culha C, Uc ZA, Dellal FD, Serter R, et al. (2010) Serum fibroblast
growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol 26:
819–826.
43. Sahin SB, Ayaz T, Cure MC, Sezgin H, Ural UM, et al. (2014) Fibroblast
growth factor 21 and its relation to metabolic parameters in women with
polycystic ovary syndrome. Scand J Clin Lab Invest.
Irisin and Bone in Athletes and Non-Athletes
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e100218